-
Mashup Score: 4A Study of PARG Inhibitor IDE161 in Participants with Advanced Solid Tumors | Jefferson Health - 1 year(s) ago
Copyright © 2023 Thomas Jefferson University Hospitals. All Rights Reserved. Jefferson holds itself accountable, at every level of the organization, to nurture an environment of inclusion and respect, by valuing the uniqueness of every individual, celebrating and reflecting the rich diversity of its communities, and taking meaningful action to cultivate an environment of fairness, belonging &…
Source: www.jeffersonhealth.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0
African American Families Fighting Parental Cancer TogetherThe purpose of this study is to test the usefulness of a family-based program for African American parents/primary caregivers with newly diagnosed solid tumor cancer and their adolescent children. The program is designed to promote family communication reduce and depressive symptoms for adolescence.Learn MoreProtocol…
Source: www.jeffersonhealth.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#TrialTuesday: "African American Families Fighting Cancer Together" provides free online support for parents/caregivers who have been diagnosed with cancer & their children. Eligible families may receive up to $290 for their time & effort: https://t.co/ksTVhY3CXp https://t.co/rK2FG05tAG
-
-
Mashup Score: 0
A Phase III Double-Blind, Randomised, Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Docetaxel Versus Placebo + Docetaxel as Treatment for Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC)The objective of this study is to demonstrate superiority of capivasertib + docetaxel relative to placebo + docetaxel by assessment of overall survival (OS) in…
Source: www.jeffersonhealth.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#TrialTuesday: Dr. Patrick Mille is leading a #ClinicalTrial assessing the combination of capivasertib + docetaxel vs. docetaxel + placebo in patients with metastatic castration-resistant #ProstateCancer: https://t.co/UXDNPcJBfJ #ProstateCancerAwarenessMonth https://t.co/B7CKxrZRRc
-
-
Mashup Score: 1
This immunotherapy developed by a Jefferson neurosurgeon may increase the lifespan of patients with fast-growing and aggressive brain tumor.
Source: www.jeffersonhealth.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#TrialTuesday: A phase IIb trial is now enrolling patients with glioblastoma. IGV-001, a novel immunotherapy developed by Jefferson neurosurgeon & SKCC member Dr. David Andrews, may increase the lifespan of patients with this aggressive tumor. https://t.co/lGicw6QqTJ @imvax_inc https://t.co/dxIb0iLgiD
-
-
Mashup Score: 0Comparing the Addition of Radiation Either Before or After Surgery for Patients With Brain Metastases - Full Text View - ClinicalTrials.gov - 2 year(s) ago
Comparing the Addition of Radiation Either Before or After Surgery for Patients With Brain Metastases – Full Text View.
Source: classic.clinicaltrials.govCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#TrialTuesday: Dr. Wenyin Shi is leading a phase III trial comparing stereotactic radiosurgery, a type of #RadiationTherapy, before or after surgery to treat patients whose cancer has spread - or metastasized - to the brain. #RadOnc #BrainMets @NRGonc 🔗https://t.co/uwISg05GlX https://t.co/qEjblj8P3P
-
-
Mashup Score: 0
ENVASARC: Envafolimab And Envafolimab With Ipilimumab In Patients With Undifferentiated Pleomorphic Sarcoma Or Myxofibrosarcoma – Full Text View.
Source: classic.clinicaltrials.govCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#TrialTuesday: Dr. Atrayee Basu-Mallick is leading the ENVASARC trial at SKCC, which is investigating the injectable PD-L1 antibody envafolimab with & without ipilimumab to treat undifferentiated pleomorphic sarcoma/myxofibrosarcoma #SarcomaAwarenessMonth: https://t.co/ufZF7hvbC7 https://t.co/R0ms59Kmi2
-
-
Mashup Score: 0
A Text-based Intervention in Improving Adherence to Hormone Therapy in Patients With Stage I-III Hormone Receptor Positive Breast Cancer – Full Text View.
Source: www.clinicaltrials.govCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#TrialTuesday: Side effects may prevent women with HR+ #BreastCancer from adhering to adjuvant hormone therapy. A #ClinicalTrial led by Dr. Kuang-Yi Wen is studying how well a text-based intervention improves adherence to hormonal therapy: https://t.co/KqNX7KMJb8 https://t.co/DuaR0G6yE3
-
-
Mashup Score: 1A Phase 2b Clinical Study With a Combination Immunotherapy in Newly Diagnosed Patients With Glioblastoma - Full Text View - ClinicalTrials.gov - 2 year(s) ago
A Phase 2b Clinical Study With a Combination Immunotherapy in Newly Diagnosed Patients With Glioblastoma – Full Text View.
Source: www.clinicaltrials.govCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#TrialTuesday: We are now accruing patients for a #ClinicalTrial to assess whether IGV-001, a personalized immunotherapeutic product, improves survival in newly diagnosed #glioblastoma patients. #BrainCancerAwarenessMonth @imvax_inc ➡️ https://t.co/O3F80PgXuW https://t.co/Bt3lDZjnCs
-
-
Mashup Score: 2
QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer – Full Text View.
Source: www.clinicaltrials.govCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#TrialTuesday: QUILT-3.032 is a phase II/III trial investigating intravesical Bacillus Calmette-Guerin plus IL-15 superagonist ALT-803 in BCG-unresponsive non-muscle invasive #BladderCancer. Dr. Edouard Trabulsi @ETUroOnc is PI. ➡️ https://t.co/kdQ4QCnpTy #BladderCancerAwareness https://t.co/CsGYlEmEFT
-
-
Mashup Score: 2
Safety and Efficacy of Repeat Administration of Ad/PNP and Fludarabine Phosphate in Patients With Local Head/Neck Cancer – Full Text View.
Source: www.clinicaltrials.govCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#TrialTuesday: @JosephMCurryMD is leading a #ClinicalTrial evaluating safety & efficacy of repeat administration of Ad/PNP & fludarabine phosphate in patients with head & neck cancer: https://t.co/SECskKyM7e #HeadAndNeckCancerAwarenessMonth #immunooncology @Geovax_News https://t.co/9Ge4O88vr2
-
#TrialTuesday: @KayvanZarrabi is leading a first-in-human trial evaluating the safety, efficacy, & tolerability of the PARG inhibitor IDE161 as a monotherapy in metastatic solid tumors harboring BRCA1/2 mutations or other HR defects now enrolling at SKCC: https://t.co/0RatzX3BpL https://t.co/Eg0fWl27bq